Prescient Therapeutics Ltd has released a press release.
Prescient Therapeutics: Replacement Entitlement Offer Prospectus
Filed with ASX ·
6ix hasn’t read this filing yet.
Prescient Therapeutics Limited on 6ix
Earlier from Prescient Therapeutics
- Offer Document
- PTX Secures $7.0M Capital Raising
- March 2016 Appendix 4C - Quarterly
- Executive Management Change
- Virax Rights Offer Documentation - 25 May 2011
Later from Prescient Therapeutics
- Yale Joins PTXs Phase 1b/2 AML Clinical Trial
- June 2016 Appendix 4C - Quarterly
- Change to exercise price of options
- USPTO Grants Allowances for Two PTX-200 Patents
- Appendix 4E and 2016 Annual Report
Follow Prescient Therapeutics into a list and get an email when it puts out news.
Follow Prescient Therapeutics